This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi. A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis-C pills combined, according to new data from IMS Health. (AP Photo/Gilead Sciences)

The big Pharma trends of 2014

From the debate over drug pricing to the heightened restructuring of an industry, the region’s pharmaceutical sector has experience ...

12 years ago